Immunic Inc
Company Profile
Business description
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Contact
1200 Avenue of the Americas
Suite 200
New YorkNY10036
USAT: +1 332 255-9818
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
95
Stocks News & Analysis
stocks
ASX property share lifts guidance despite sector headwinds
stocks
Why stocks sometimes fall for no obvious reason
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,945.20 | 66.70 | 0.75% |
| CAC 40 | 8,207.89 | 34.78 | 0.43% |
| DAX 40 | 25,177.80 | 7.09 | -0.03% |
| Dow JONES (US) | 50,662.00 | 200.32 | 0.40% |
| FTSE 100 | 10,505.01 | 13.62 | 0.13% |
| HKSE | 25,328.23 | 271.22 | -1.06% |
| NASDAQ | 26,621.93 | 34.26 | -0.13% |
| Nikkei 225 | 64,999.41 | 3.32 | 0.01% |
| NZX 50 Index | 13,227.81 | 158.07 | 1.21% |
| S&P 500 | 7,514.27 | 4.85 | -0.06% |
| S&P/ASX 200 | 8,717.70 | 65.50 | 0.76% |
| SSE Composite Index | 4,093.73 | 51.65 | -1.25% |